Colitis induced by combination use of anlotinib and sintilimab
10.3760/cma.j.cn114015-20201215-01241
- VernacularTitle:安罗替尼与信迪利单抗联用致结肠炎
- Author:
Yuexin DONG
1
;
Dan YU
;
Jianghua SHEN
;
Yan ZHANG
;
Yanqi CHU
Author Information
1. 首都医科大学宣武医院药学部，北京 100053
- Publication Type:Journal Article
- Keywords:
Antineoplastic agents;
Colitis;
Anlotinib;
Sintilimab
- From:
Adverse Drug Reactions Journal
2021;23(10):546-548
- CountryChina
- Language:Chinese
-
Abstract:
A 69-year-old male patient with retroperitoneal sarcoma received anlotinib capsules (12 mg orally once daily for 14 days, interruption for 7 days) and sintilimab injection (IV infusion of 200 mg on the first day) and 21 days was a cycle. He had no history of diarrhea and previous enteroscopy showed no obvious abnormality. So the diarrhea, which occurred after 18 days of treatments, was considered to be related to the combination use of anlotinib capsules and sintilimab injection. Above 2 drugs were stopped and hormone and symptomatic treatments were given. Six days later, the patient′s diarrhea was improved, and enteroscopy showed colitis. Considering the primary disease, the patient was treated with oral anlotinib capsule monotherapy with the same dose as before. Two days later, the patient had diarrhea again, which was more serious than before, and the anlotinib capsules were stopped again. After 14 days of hormone shock therapy, anti-infection therapy, and symptomatic treatments, the patient′s diarrhea was improved.
